Compare Nuvation Bio Inc. Class A Common Stock (NUVB) vs Under Armour Inc Class A (UA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Nuvation Bio Inc. Class A Common Stock vs Under Armour Inc Class A — how do they compare? Nuvation Bio Inc. Class A Common Stock trades at $5.03 (market cap $1.74B), while Under Armour Inc Class A trades at $4.82 (market cap $2.07B). The key difference: Under Armour Inc Class A is the larger of the two by market cap, and Nuvation Bio Inc. Class A Common Stock is more actively traded (9,289,619 versus 2,680,141). Which is the better fit depends on your goals — on Pluang, investors hold Nuvation Bio Inc. Class A Common Stock for 1 Days and Under Armour Inc Class A for 18 Days on average.
| NUVB | UA | |
|---|---|---|
Market Cap | $1.74B | $2.07B |
Volume | 9,289,619 | 2,680,141 |
Sector | Health | Consumer Cyclical |
52-Week High | $9.54 | $7.88 |
52-Week Low | $3.41 | $3.96 |
Typical Hold Time | 1 Days | 18 Days |
Enterprise Value | $1.33B | $3.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Under Armour (UA) trades at $4.81, up 2.34% with a bullish technical signal despite mixed fundamentals. The company reported declining revenues ($5.16B in 2025, $4.9B in 2026) and negative net income margins (-9.99%), though recent quarterly earnings showed beats in Q4 2025 and Q2 2026. Analyst sentiment is divided with 39.71% buy ratings, while cash flow trends show significant outflows (-$362M net in 2025).
The outlook remains challenging with revenue declines and profitability concerns, but the stock's low P/S ratio (0.41) may attract value investors. Key risks include sustained negative cash flow, competitive pressures, and execution on turnaround strategies. Near-term performance hinges on Q3 2026 earnings and guidance updates.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Nuvation Bio Inc. Class A Common Stock
Nuvation Bio Inc. is a biopharmaceutical company focused on oncology, developing novel cancer treatments including taletrectinib (marketed as IBTROZI), a ROS1 inhibitor, and safusidenib, a brain-penetrant IDH1 inhibitor.
Read more on NUVB →About Under Armour Inc Class A
Under Armour is a leading inventor, marketer, and distributor of branded athletic performance apparel, footwear, and accessories. Built on the 'technical' performance of synthetic fabrics, the company is currently undergoing a multi-year brand evolution centered on premium product innovation, operational rigor, and a renewed focus on its North American core under the guidance of founder Kevin Plank.
Read more on UA →
